Gastric and duodenal ulcers during pregnancy.
The frequency, symptoms, and complication rate of PUD seem to decrease during pregnancy. Yet clinicians often have to treat dyspepsia or pyrosis of undetermined origin during pregnancy because the frequency of pyrosis significantly increases during pregnancy, and clinicians reluctantly perform EGD during pregnancy for pyrosis to differentiate reliably between GERD and PUD. Dyspepsia or pyrosis during pregnancy is initially treated with dietary and lifestyle modifications. If the symptoms do not remit with these modifications, sucralfate or antacids, preferably magnesium-containing or aluminum-containing antacids, should be administered. Histamine2 receptor antagonists are recommended when symptoms are refractory to antacid or sucralfate therapy. Ranitidine seems to be a relatively safe H2 receptor antagonist. If symptoms continue despite H2 receptor antagonist therapy, the patient should be evaluated for possible EGD or PPI therapy. Pregnant women with hemodynamically significant upper gastrointestinal bleeding or other worrisome clinical findings should undergo EGD. Indications for surgery include ulcer perforation, ongoing active bleeding from an ulcer requiring transfusion of six or more units of packed erythrocytes, gastric outlet obstruction refractory to intense medical therapy, and a malignant gastric ulcer without evident metastases.
Cappell
Mitchell S
MS
Division of Gastroenterology, Department of Medicine, Woodhull Medical Center, 760 Broadway Avenue, Brooklyn, NY 11206, USA.
D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004381:Duodenal Ulcer / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy; D016145:Endoscopy, Digestive System; D005260:Female; D006801:Humans; D011247:Pregnancy; D011248:Pregnancy Complications; D013276:Stomach Ulcer / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy
D000897:Anti-Ulcer Agents